Dr. Jeff M. Bronstein, MD
Neurology (Neurology Physician)
300 Medical Plaza, #b200
Los Angeles, CA 90095
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Geffen School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 195
Licensed in California since 1990, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: University of California, Geffen School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license G67890 (first issued 1990; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ronald Reagan UCLA Medical Center Los Angeles, CA
- Santa Monica - UCLA Med Ctr & Orthopaedic Hospital Santa Monica, CA
Medical groups
- The Regents of the University of California (97 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 195
- Services billed
- 506
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 286 | 137 |
| Established patient office or other outpatient visit, 30-39 minutes | 52 | 41 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 30 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Los Angeles, CA | 285 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Los Angeles, CA | 202 |
| Nuplazid (pimavanserin tartrate) | 174 |
| Rytary (carbidopa/levodopa) Other prescribers in Los Angeles, CA | 148 |
| Donepezil Hcl Other prescribers in Los Angeles, CA | 134 |
| Carbidopa-Levodopa-Entacapone (carbidopa/levodopa/entacapone) | 118 |
| Quetiapine Fumarate Other prescribers in Los Angeles, CA | 97 |
| Rasagiline Mesylate | 91 |
| Escitalopram Oxalate Other prescribers in Los Angeles, CA | 85 |
| Amantadine (amantadine hcl) Other prescribers in Los Angeles, CA | 79 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 10 payments worth $1,595 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $1,595 |
|---|
| Travel and Lodging | $1,227 |
|---|---|
| Food and Beverage | $368 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Jun 13, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $593 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 12, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $406 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 12, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $131 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 12, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $96.19 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $48,589 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
Ultragenyx Pharmaceutical Inc. · Active, not recruiting · NCT04884815
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.